Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

Related Articles by Review for PubMed (Select 15501978)

1.

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA.

Clin Cancer Res. 2004 Oct 15;10(20):6985-92.

2.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
5.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
6.

Monoclonal antibodies and neuroblastoma.

Miraldi F.

Semin Nucl Med. 1989 Oct;19(4):282-94. Review.

PMID:
2678480
7.

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Miederer M, Scheinberg DA, McDevitt MR.

Adv Drug Deliv Rev. 2008 Sep;60(12):1371-82. doi: 10.1016/j.addr.2008.04.009. Epub 2008 Apr 23. Review.

8.
9.

Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments.

Bestagno M, Occhino M, Corrias MV, Burrone O, Pistoia V.

Cancer Lett. 2003 Jul 18;197(1-2):193-8. Review.

PMID:
12880981
10.

Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.

Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD.

Int J Rad Appl Instrum B. 1989;16(2):111-20. Review. No abstract available.

PMID:
2497088
11.

The diagnostic and therapeutic management of leptomeningeal carcinomatosis.

Pavlidis N.

Ann Oncol. 2004;15 Suppl 4:iv285-91. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk